Eagle Pharmaceuticals appoints Rich Edlin to the Board of Directors and its Nominating and Corporate Governance Committee

– USA, NJ – Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that its Board of Directors has approved the appointment of Richard A. Edlin, Vice Chair, Chair of the Litigation Practice in New York, and a member of the Executive Committee of the law firm Greenberg Traurig, LLP, a top international multi-practice law firm, to the Company’s Board of Directors, and as a member of the Board’s Nominating and Corporate Governance Committee, each effective as of March 17, 2017.

“Rich’s extensive experience in commercial and intellectual property litigation, as well as the life sciences arena, both in and out of court, along with his vast professional and community accomplishments, will bring invaluable knowledge and insight as we continue to execute on our strategy,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

About Richard A. Edlin

Mr. Edlin, 56, is a seasoned litigator with broad experience in both trial and appellate courts including the U.S. Supreme Court and the Delaware Supreme Court. He has tried cases in federal and state courts all over the country and has handled domestic and international arbitrations.

At Greenberg Traurig, Mr. Edlin handles a wide variety of litigation and routinely acts for companies and their management in areas such as securities, general commercial and contractual disputes, antitrust and intellectual property.

Mr. Edlin is a member of the Board of Trustees of the Urban Justice Center; a member of the Board of Directors for Judges and Lawyers Breast Cancer Alert (JALBCA); a member of the Board of Governors of Hackensack University Medical Center, where he serves on the finance committee; a trustee of The Carnegie Council for Ethics in International Affairs, where he serves as Treasurer and chairs the development and finance committees; a member of the Board of Governors, American Friends of Tel Aviv University; a member of the Economic Club of New York; a fellow of the Litigation Council of America; and a trustee of New Jersey SEEDS, among other professional and community activities.

Mr. Edlin received his B.A. degree from Tufts University, magna cum laude in history and received his law degree from Columbia University School of Law, where he was a Harlan Fiske Stone Scholar and Notes editor of the Columbia Journal of Environmental Law. Following his graduation, Mr. Edlin served as law clerk to Hon. Lee P. Gagliardi of the United States District Court for the Southern District of New York.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA’s 505(b)(2) regulatory pathway.

For more information : http://www.eagleus.com

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here the original post =>

Comments are closed.